Lightcalls.com
 

Called alternately Gur-mar or Mera-...

Called alternately Gur-mar or Mera-singi in Hindi, Meshasringi (meaning "ram's horn") in Sanskrit, "Periploca of the Woods" in English, wald-schlinge in German, and Sarpadarushtrika Meshasringi in Ayurvedic Medicine, Gymnema sylvestre is a timbered climbing plant that grows in the tropical forests of central and southern India. It also happens to be a first-rate warrior against diabetes.

History and traditional uses

A member of the botanical family, Asclepiadacerae, an of the best variety of Gymnema was growing in the Indian city of Goa, ages before the year 1498 when the green-and-red royal Portuguese flag first waved in the warm agitations that grace the Malabar Coast of southwest India. It grew there during the Indian occupation of 1961-1962 which restored Indian method to Goa. And this outstanding botanical will continue to put forth there for as long as geology and humankind permit.

In classical Ayurveda, Gymnema sylvestre has been used for stomach turn upside downs and as a diuretic. It was noted, steady as far back as the first centenary A.D., that Gymnema successfully "destroyed" exces sugars in the corpse a condition now recognized as diabetes.



An interesting passage from the Pharmacographia Indica journal, published in 1972 by means of the Hamdard National Foundation, goe as follows:

It [Gymnema sylvestre] is also in estimate amongst the Hindus as a relief for snake bite, the triturateed root being applied to the part bitten and a decoction administered internally. Its use for this intent is well known to the natives of the Concan [] also to the natives of Southern India. [] Roxburgh describes the plant in subordination to the name of Asclepias geminata, and remarks that the small gold-colored flowers [...] look like fine pearls stake in gold.

He says nothing of its medicinal properties.

We can, however, gaze at a number of important studies, a certain quantity of of which attempt to break down this botanical into its molecular constituents others of which reveal beneficial medicinal actions attributed to supplementation with leaf-extracts obtained from Gymnema sylvestre

Component novel research, medicinal properties

What's in it? The leaves have special plant-sugar pay by substitutions called "triterpine saponins." Pharmacographia Indica voiced the suggestion that these combines be called gymnemic acids, a suggestion that was first made according to D. Hooper in 1887, and subsequently taken by way of researchers in 1959 (Warren and Pfaffmann), 1966 (Yackzan), and 1967 (Stocklig), among others.

According to Joseph E Sinsheimer, et al., in a 1970 article that appeared in the Journal of Pharmaceutical Sciences, gymnemic acid was set up to be a "complex mixture" of at least nine acidic plant sugars (type of saponins, called glycosides).

A partial listing of Gymnema's ingredients includes:

* hentriacontane;

* chlorophyll;

* phytin;

* resins;

* anthraquinone derivatives; and

* dammarane saponins.

What about dosing and percentages of gymnemic acids? A 250 mg complement dose, twice daily, represents the extract when the gymnemic acids have been standardized at 25% The 75 mg extract, taken twice-daily, provides 75% gymnemic acids. Nevertheless, a profitable general rule of thumb is: 150 mg three times a day.

What is its in the greatest degree impressive clinical application?

Diabetes. As early as 1930 researchers were also reporting the plant's blood-glucose (blood-sugar) lowering actions. In fresh India, extracts of Gymnema's leaves are used fortunately either alone or in combination, with other Ayurvedic composes as a remedy against diabetes mellitus.

What is diabetes mellitus? Actually, there are sum of two units forms. Type I diabetes, or insulin-dependent diabetes, is a peremptory chronic form of diabetes brought forward by insufficient production of insulin, resulting in abnormal metabolism of carbohydrates, proteins, and fats.

This form of diabetes normally appears in childhood, or adolescence, and is characterized at excessive thirst, frequent urination, a build up of acids in the body--or a decrease in bicarbonates (acidosis), and heightened sugar horizontals in blood and urine (glucosuria).

Type II diabetes, or non-insulin-dependent diabetes, is a les hard form of the disease that usually appears first in adulthood. frequently manifesting no symptoms, and growing worse with obesity and physical inactivity, this form is treated with dietary changes and exercise.

In 1990 at the Dr Ambedkar Institute of Diabetes (Kilpauk Medical body Hospital), Madras, E.R.B. Shanmugasundaram, et al., gave 400 mg/day of Gymnema sylvestre extract to 27 patients with model I diabetes, the severe form.

The issues indicate that insulin requirements and excessive excretion of diabetic sugar in the urine (glucosuria) were reduc in 22 patients; progeny sugar (glucose) levels were reduc in 25

A lack of negative side forces The authors, furthermore, add that: "patients forward [Gymnema sylvestre extract] therapy did not report any undesirable side events such as nausea, vomiting, lassitude, insomnia, [] or any gastrointestinal disturbances [] Five patients reported a faculty of perception of greater well being characterized by dint of alertness of mind and carcass during their daily chores, catching a bus at vulgar herded stop, playing games and writing examinations."



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.